Association between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients with COVID-19

Link to article at PubMed

Mayo Clin Proc Innov Qual Outcomes. 2021 Mar 14. doi: 10.1016/j.mayocpiqo.2021.02.002. Online ahead of print.

ABSTRACT

OBJECTIVE: To determine the association between chronic statin use and mortality in patients hospitalized with COVID-19.

PATIENTS AND METHODS: We identified a retrospective cohort of patients requiring admission at the Mayo Clinic using our enterprise-wide COVID-19 registry from March 1st, 2020, through September 30th, 2020. Available information included age, gender, use of statins, medical comorbidities, and 30-day mortality. We estimated the association of statins with 30-day mortality using odds ratios (OR) and 95% confidence intervals (CI) from logistic regression modeling.

RESULTS: 1295 patients between the ages of 30 and 80 tested positive for COVID-19 and required admission during the study period, of whom 500 (38.6%) were taking statins at admission. Patients taking statins were older and more likely to have diabetes mellitus or congestive heart failure. Within 30 days of diagnosis, 59 (4.6%) died. In multivariable analysis, statin users did not have statistically different odds of death within 30 days with OR of 1.14 (95% CI: 0.64-2.03, P=.67) compared to non-users.

CONCLUSIONS: Patients with COVID-19 taking statins had similar 30-day mortality to those not taking statins, after adjusting for relevant covariates. Although this is partly influenced by a higher prevalence of risk factors for more severe COVID-19 presentation not entirely adjusted for by the Charlson Comorbidity Index, these data would not support statins as a likely therapeutic intervention for COVID-19 in the hospital setting.

PMID:33748678 | PMC:PMC7955930 | DOI:10.1016/j.mayocpiqo.2021.02.002

Leave a Reply

Your email address will not be published.